How Does Relfydess Compare to Alluzience® and Azzalure®?

The launch of Relfydess in Germany has introduced a new era for injectable aesthetics. But how does Relfydess compare to Galderma’s other offerings, Alluzience® and Azzalure®, particularly in terms of onset of action and duration of effect? Here’s a breakdown of the key scientific differences based on published data.

Onset of Action

One of the most significant factors when choosing a botulinum toxin treatment is how quickly it delivers visible results.

• Relfydess: Clinical trials reveal that 39% of patients observed visible improvements in frown lines as early as day one after treatment. This rapid onset offers a distinct advantage for patients seeking quicker results. (Source)
• Alluzience®: Data supporting its approval also demonstrated improvements starting from day one, making it comparable to Relfydess™ in terms of speed. (Source)
• Azzalure®: Clinical experience suggests an onset of action typically within 2 to 3 days, slightly slower than its liquid counterparts.

Duration of Effect

The longevity of results is another crucial consideration, especially for patients looking to minimise the frequency of treatments.

• Relfydess: Findings from the phase III READY clinical trial program showed that up to 75% of patients maintained improvements for six months following a single treatment, making it one of the longest-lasting neuromodulators available. (Source)
• Alluzience®: Like Relfydess, improvements have been shown to last up to six months, positioning it as another long-lasting option. (Source)
• Azzalure®: The duration of effect generally ranges from three to four months, depending on individual factors and the treated area. While effective, it may require more frequent treatments compared to Relfydess and Alluzience®.

What Sets Relfydess Apart?

Relfydess stands out due to its use of PEARL™ Technology, which preserves the molecule’s integrity and delivers a highly active, complex-free formula. This technology not only enhances its precision and safety but also contributes to its longer-lasting results.

Additionally, being the first and only ready-to-use liquid neuromodulator, Relfydess offers unmatched convenience for practitioners and ensures consistent preparation, reducing the risk of dilution errors.

Choosing the Right Option for You

When deciding between Relfydess™, Alluzience®, and Azzalure®, the choice depends on your priorities:

• Choose Relfydess™ if you value quick results and longer duration.
• Choose Alluzience® if you need a ready-to-use product for frown lines.
• Choose Azzalure® if affordability and reliability are key.

Each product has its strengths, but Relfydess™ represents the next step in injectable treatment innovation.

Stay Ahead with the Latest in Aesthetics

The introduction of Relfydess in Germany is an exciting milestone for patients and practitioners. With its rapid onset, extended duration, and cutting-edge technology, it is poised to redefine injectable treatments.

While it’s not yet available in the UK, Riverbanks Clinic remains committed to staying at the forefront of aesthetic innovations. If you’d like to explore our current wrinkle-reducing treatments or discuss your aesthetic goals, book a consultation at riverbanksclinic.co.uk/book or call us on 01582 762877.

Stay tuned for updates on when this revolutionary treatment will be available near you.

Relfydess Training for Medical Professionals

For clinicians ready to integrate the latest innovation in botulinum toxin therapy, we offer dedicated Relfydess training at Riverbanks Wellness Clinic. These in-depth workshops are limited to 4–5 delegates to ensure personal guidance and practical confidence. Training includes the use of Relfydess on the day, comprehensive course materials, and optional models (available on request). Just 10 minutes from Luton Airport, our award-winning clinic provides the perfect setting for focused learning. Led by Dr Ravi Jain, one of the first UK trainers in Relfydess, these sessions are ideal for practitioners who want to deepen their understanding and offer patients the benefits of this next-generation toxin.